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Previewsexploring the biology of human adipocyte
progenitor cells in their microenvironment
and for testing whether findings obtained
with a rodent model are relevant to
human physiological or patho-physiolog-
ical conditions.
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Millions of diabetic patients are waiting for better treatment options, ideally by replenishing the lost or
dysfunctional insulin-producing b cell mass. Yi et al. (2013) now identify Betatrophin, a hormone that
specifically increases b cell proliferation with promising therapeutic potential.Pancreatic b cells are perfect sensors of
blood glucose levels and secrete just the
right amount of insulin into the blood-
stream to systemically regulate glucose
and energy homeostasis. Type 1 diabetes
results from autoimmune destruction of b
cells, whereas in type 2 diabetes, a failure
of b cells to compensate for peripheral
insulin resistance leads to exhaustion,
dedifferentiation, and loss of functional b
cell mass. Unfortunately, neither pharma-
cological treatment nor insulin injections
can fully substitute for endogenous b cell
function to prevent uncontrolled hypergly-
cemia and the devastating micro- and
macrovascular complications associated
with both forms of diabetes. Thus, the
only way for a better treatment and a
potential cure for the disease is to replace
or regenerate the lost or dysfunctional b
cell mass (Bonner-Weir and Weir, 2005).
Work by the Melton laboratory now
reports on Betatrophin, a hormone that
specifically increases b cell mass in mice
and therefore raises hope for regenerative
b cell therapy in humans (Yi et al., 2013).It has long been known that insulin
resistance causes compensatory b cell
mass expansion in the pancreas, likely
due to circulating growth factor(s)
(Michael et al., 2000). Identification of
these factors could possibly allow
regenerative b cell therapy. Gut-derived
incretins, macrophage-derived cyto-
kines, muscle-derived myokines, and
adipocyte-derived adipokines have all
been shown to increase b cell mass
but remain unchanged in the peripheral
bloodstream of insulin-resistant mice (El
Ouaamari et al., 2013). In a recent
study published in Cell (Yi et al., 2013),
a novel pharmacological mouse model
of severe insulin resistance was used
to identify these unknown factor(s) that
trigger compensatory b cell prolifera-
tion. For this purpose, a 43 amino
acid inhibitory peptide with high affinity
and selectivity for the insulin receptor
was infused into mice. Inhibition of
insulin signaling caused dose-dependent
hyperglycemia and glucose intolerance
in the short period of 1 week. Moreover,plasma insulin levels were increased,
likely due to compensatory b cell pro-
liferation and b cell mass expansion
triggered by expression changes of cell-
cycle regulators. As the inhibitory
peptide did not directly act on b cells
per se, further genome-wide expression
profiling of metabolically active tissues
(liver, fat, muscle, and b cells) was used
to identify potential mediators of this
response. This pointed to Betatrophin, a
secreted protein of 198 amino acids
that is highly conserved in all mammalian
species. Betatrophin shows increased
expression in liver and fat in mouse
models that expand b cell mass upon
insulin resistance, pregnancy, or leptin
deficiency. Intriguingly, transgenic over-
expression of Betatrophin in the liver
induces a rapid, robust, and specific
increase of b cell proliferation and
improves glucose tolerance in young
adult mice. Together, these results sug-
gest that Betatrophin may be one of the
factors that we have searched for for
over a decade, a hormone that triggerslism 18, July 2, 2013 ª2013 Elsevier Inc. 5
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Figure 1. bCell Proliferation Is Induced byBetatrophin
by an as-of-yet Unknown Mechanism
(A) The Betatrophin hormone is upregulated in liver and white
and brown fat during compensatory b cell proliferation. It
either acts alone or in combination with other factor(s) to
increase b cell proliferation and mass. The islet of Langerhans
contains replication-refractory (orange) and replication-
competent b cells (red) that might differentially react to mito-
genic stimulation.
(B) Betatrophin and/or other circulating factors trigger a spe-
cific or combinatorial response via unknown receptors and
signaling pathways. This leads to cell-cycle reentry of b cells
through the regulation of cell-cycle activators and inhibitors.
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Previewscompensatory b cell proliferation
upon insulin resistance.
Although these are exciting find-
ings, it is now important to under-
stand how Betatrophin acts at the
systemic, cellular, and molecular
levels. Notably, genome-wide asso-
ciation studies have linked the
human homolog gene C19ORF80
to blood lipid levels (Teslovich
et al., 2010). This association is
functionally relevant, as three
groups independently identified Be-
tatrophin (formerly named Lipasin,
RIFL, and ANGPTL8) as a nutrition-
ally regulated factor that controls
fatty acid metabolism and serum tri-
glyceride levels (reviewed in Zhang
and Abou-Samra, 2013). Thus, it
will now be crucial to investigate
whether Betatrophin alone or in
combination with changes in lipid
metabolism triggers b cell prolifera-
tion. Testing recombinant Betatro-
phin on isolated islets of Langerhans
could clarify if the hormone acts
directly on b cells. Furthermore,
injections of biologically active
Betatrophin in mice will reveal its
dose response and specific and
combinatorial effects on glucose
and lipid metabolism. Finally, it willbe important to determine (1) if Betatro-
phin on its own is necessary and (2) the
key to trigger the compensatory b cell
expansion upon insulin resistance using
a Betatrophin mouse knockout model.
Once the direct effect of Betatrophin on
b cell proliferation is clarified, the door to
investigate the cellular and molecular
mechanism of action is opened. The
magnitude, rapidity, and specificity of b
cell replication upon transgenic Betatro-
phin expression is remarkable, especially
because it exceeds any compensatory
proliferative response described so far in
other mouse models (Yi et al., 2013).
How Betatrophin elicits this potent
response is currently unclear. One possi-
bility is that Betatrophin might stimulate
a specific subpopulation of b cells that is
replication competent (Kushner, 2013)
(Figure 1A), such as the rare insulin+ self-
renewing andmultipotent progenitor pop-
ulation that was recently described in
mouse and human islets (Smukler et al.,6 Cell Metabolism 18, July 2, 2013 ª2013 Els2011). Another possibility is that Betatro-
phin acts on b cells alone or in combina-
tion with other secreted factors in a
synergistic or additive manner. For
example, the combination of lipids and
pregnancy hormones has been shown
to additively regulate b cell proliferation
during gestation (Brelje et al., 2008). The
identification of receptors and signaling
pathways that regulate b cell proliferation
upon Betatrophin gain- and loss-of-
function will address these issues. Insulin
receptor signaling may not mediate this
response since Betatrophin was discov-
ered in a pharmacological model of
insulin resistance. However, studying G
protein-coupled, ion channel- linked, or
enzyme-linked receptors and down-
stream pathway activation could provide
insights into how the hormone regulates
cell-cycle activators and inhibitors that
tightly balance b cell proliferation (Fig-
ure 1B). Clarifying Betatrophin’s mecha-
nism of action and generating biologicalevier Inc.active hormone will move regenera-
tive therapy one step closer to the
clinic.
Toward this aim, it will be neces-
sary to show that Betatrophin acts
selectively on b cells and does not
trigger growth of other cell types in
the mammalian body. Both benefi-
cial regenerative effects on b cell
replication and possible adverse
effects due to changes in lipid meta-
bolism have to be considered.
Moreover, adaptive b cell regenera-
tion severely declines with age in
mammals (Kushner, 2013), and it is
currently not clear whether promot-
ing b cell replication or restoring b
cell differentiation allows regenera-
tive therapy (Talchai et al., 2012).
Thus, it remains to be tested if Beta-
trophin can also elicit b cell mass
expansion in aged or diabetic mice
with restricted regenerative capacity
or dedifferentiated b cells, respec-
tively. Further experiments will
soon tell us if Betatrophin allows
regenerative therapy in humans.
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